Table 3.
The IC50 and CR of AFB1-specific mAbs reported in previous literature.
| References | AFB1 mAb | Coupling Method | Mode | IC50 of AFB1 (μg/L) |
CR (%) a | ||||
|---|---|---|---|---|---|---|---|---|---|
| AFB2 | AFG1 | AFG2 | AFM1 | AFM2 | |||||
| This study (2022) | mAb 2A11 | OAE | icELISA b | 6.28 | 4.35 | 2.30 | <1.0 | <0.1 | <0.1 |
| Jiang et al. (2021) [30] | mAb 1F7 | OAE | icELISA | 0.15 | 35.07 | 8.75 | 1.15 | - c | - |
| Li et al. (2017) [23] | mAb 1B5 | OAE | icELISA | 0.012 | 4.0 | 3.0 | <0.1 | <0.1 | <0.1 |
| mAb 2F12 | OAE | icELISA | 0.01 | 5.0 | 2.0 | 0.2 | <0.1 | 0.2 | |
| Zhang et al. (2011) [32] | mAb 3G1 | SA | icELISA | 1.6 | 6.4 | <0.02 | <0.02 | - | - |
| Kolosova et al. (2006) [31] | mAb 34 | OAE | dcELISA d | 0.62 | 5.0 | 31.0 | 2.4 | - | - |
Note: (a) The data were calculated using the CR of AFB1 as 100%; (b) icELISA: indirect competitive enzyme-linked immunosorbent assay; (c) -: no detection; (d) dcELISA: direct competitive enzyme-linked immunosorbent assay; SA: semi-acetal.